Artificial intelligence trained to find disease-related genes
Researchers have developed an artificial neural network using deep learning to identify genes that are related to disease.
List view / Grid view
Researchers have developed an artificial neural network using deep learning to identify genes that are related to disease.
Researchers have engineered a chip which allows 3D modelling of the blood-brain-barrier and has provided insight into how astrocytes facilitate transport of molecules.
A Frost & Sullivan award has been given to a new label-free single-cell analysis and sorting platform for utilising cutting-edge technologies.
A collaboration between Elsevier and the FDA will present an algorithm for the accurate prediction of drug-induced liver injury. Drug Target Review investigates the benefits this toxicology project will bring to the drug discovery industry.
A new study has developed a deep learning approach that analyses protein interactions, which could improve the design of drugs in the future.
Research suggests that over half of the total $5.2bn investment for artificial intelligence in pharma went to drug design applications in 2019, but overall investment is slowing.
The two organisations have entered into a two-year alliance to improve scientific exchange in the drug discovery industry.
Researchers have produced a mathematical framework enabling quick assessment of how different parameters control interactions between molecules with multiple binding sites.
Laboratory Information Management Systems (LIMS) is becoming increasingly important in GMP regulated environments in order to ensure data integrity and faster working practices.
Researchers have created an algorithm that locates and analyses DNA structures which are linked to the development of certain diseases.
A survey has shown that the pharmaceutical industry believes R&D will see a lot of benefit from digital transformation and that AI will be at the forefront.
This issue includes a discussion on the future of high-throughput screening through collaboration, an analysis of mass spectrometry as a structural biology tool and an exploration of the challenges of hit-to-lead when researching tropical diseases. Also in the issue are articles on immuno-oncology and assays.
A new discovery could lead to the development of a drug for untreatable strains of TB, which can target uptake of the very amino acid that enables the bacteria to spread within the body.
A study has shown that unintended mutations from gene editing with CRISPR-Cas9 are rare in zebrafish, providing reassurance that this technology is a valid tool with great promise for the treatment of genetic disorders.
The ICR has revealed that during drug discovery, researchers should not use general search engines and vendor catalogue information to decide on their use of chemical probes.